Abstract: Microfluidic devices and methods of quantifying fatty acids and/or specialized pro-resolving mediators and/or fatty acid metabolites present in a fluid sample on a microfluidic device are described herein. The methods include extracting fatty acid esters containing fatty acids from the fluid sample, combining the extracted fatty acid esters with a hydrolyzing agent to cleave the fatty acids from the extracted fatty acid esters and form free fatty acids, and quantifying the free fatty acids by performing a bioassay specific to the free fatty acids. Microfluidic devices and methods of quantifying fatty acid metabolites present in a fluid sample on a microfluidic device are also described herein.

Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Abstract: Fault injection testing for field programmable gate array (FPGA) devices including: interfacing with a FPGA device under test (DUT); imaging a configuration RAM (CRAM) of the FPGA DUT with a first configuration image to define a first operational function of the FPGA DUT where the CRAM includes a plurality of CRAM bits, injecting a plurality of single event upsets into a portion of the plurality of the CRAM bits while the FPGA DUT is operating; concurrently monitoring operations of the FPGA DUT and a reference FPGA device; comparing outputs of the FPGA DUT with outputs of the reference FPGA device during concurrent operations, and if there is a mismatch between the outputs of the FPGA DUT and the reference FPGA, determining that error events have occurred within the FPGA DUT; and storing the error events and CRAM location data associated with corresponding single event upsets in an error log.

Abstract: Fault injection testing for field programmable gate array (FPGA) devices including: interfacing with a FPGA device under test (DUT); imaging a configuration RAM (CRAM) of the FPGA DUT with a first configuration image to define a first operational function of the FPGA DUT where the CRAM includes a plurality of CRAM bits, injecting a plurality of single event upsets into a portion of the plurality of the CRAM bits while the FPGA DUT is operating; concurrently monitoring operations of the FPGA DUT and a reference FPGA device; comparing outputs of the FPGA DUT with outputs of the reference FPGA device during concurrent operations, and if there is a mismatch between the outputs of the FPGA DUT and the reference FPGA, determining that error events have occurred within the FPGA DUT; and storing the error events and CRAM location data associated with corresponding single event upsets in an error log.

Abstract: The disclosed embodiments concern methods, devices, and systems for identifying candidate biomarkers useful for the diagnosis, prognosis, monitoring and screening and/or as targets for the treatment of diseases and conditions in subjects, in particular autoimmune and infectious diseases. The identification of candidate biomarkers is predicated on identifying discriminating peptides present on a peptide array, which can distinguish samples from different subjects having different health conditions by the binding patterns of antibodies present in the samples.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-diethylethyl)-5-hydroxyphenyl]-1,4-dihydro-1-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-diethylethyl)-5-hydroxyphenyl]-1,4-dihydro-1-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Abstract: The disclosed embodiments concern methods, devices, and systems for identifying candidate biomarkers useful for the diagnosis, prognosis, monitoring and screening and/or as targets for the treatment of diseases and conditions in subjects, in particular autoimmune and infectious diseases. The identification of candidate biomarkers is predicated on identifying discriminating peptides present on a peptide array, which can distinguish samples from different subjects having different health conditions by the binding patterns of antibodies present in the samples.

Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Abstract: The disclosed embodiments concern non-invasive methods, and apparatus, and systems for identifying infections. The methods are predicated on identifying discriminating peptides present on a peptide array, which are differentially bound by the different mixtures of antibodies present in samples from subjects consequent to an infection relative to binding of mixtures of antibodies present in reference subjects.

Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract: Provided herein are methods, assays and devices for the detection and diagnosis of autoimmune diseases, including systemic lupus erythematosus. The methods, assays and devices provided herein analyzes binding patterns of peripheral-blood antibodies on peptide array that correlates well with current systemic lupus erythematosus clinical assessment standards.

Abstract: A cartridge casing comprising a casing tube formed substantially of metal with a closed end and an open end. The casing tube bounds at least part of a head cap entered into the open end of the tube. The head cap is fixed relative to the tube. An end wall defines the closed end opposite the head cap end of the cartridge. The end wall comprises a weakened region.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract: A cartridge casing comprises a casing tube having a first end and a head cap. The first end of the casing tube abuts and is joined with the head cap such that an orifice in the first end of the casing tube is aligned with a passage in the head cap to define a flash passage. The head cap and casing tube are held together by a deformable member.

Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.